NAT-10 Antibody (C-10): sc-271141
- NAT-10 Antibody (C-10) is a mouse monoclonal IgG1 κ provided at 200 µg/ml
- raised against a peptide mapping within an internal region of NAT-10 of human origin
- recommended for detection of NAT-10 of mouse, rat and human origin by WB, IP, IF, IHC(P) and ELISA
- m-IgG1 BP-HRP is the preferred secondary detection reagent for NAT-10 Antibody (C-10) for WB and IHC(P) applications. This reagent is now offered in a bundle with NAT-10 Antibody (C-10) (see ordering information below).
NAT-10 Antibody (C-10) is a mouse monoclonal IgG1 antibody that detects NAT-10 in mouse, rat, and human samples through various applications including western blotting (WB), immunoprecipitation (IP), immunofluorescence (IF), immunohistochemistry, and enzyme-linked immunosorbent assay (ELISA). NAT-10, a nuclear protein belonging to the UPF0202 family, features a single N-acetyltransferase domain that functions as a histone acetyltransferase, playing a crucial role in telomerase activity regulation. NAT-10 monoclonal antibody (C-10) helps researchers study how NAT-10 upregulates in response to DNA damage, suggesting involvement in genotoxic resistance and DNA repair mechanisms. NAT-10 exhibits high binding affinity for the TERT gene promoter region, essential for stimulating telomerase production. This multifaceted role indicates human telomerase complexes engage in various processes vital for maintaining genomic stability and cellular longevity. Anti-NAT-10 antibody (C-10) serves as an invaluable tool for investigating telomerase regulatory mechanisms in various biological contexts.
Alexa Fluor® is a trademark of Molecular Probes Inc., OR., USA
LI-COR® and Odyssey® are registered trademarks of LI-COR Biosciences
NAT-10 Antibody (C-10) References:
- NAT10-mediated mRNA N4-acetylcytidine modification promotes bladder cancer progression. | Wang, G., et al. 2022. Clin Transl Med. 12: e738. PMID: 35522942
- Acetyltransferase NAT10 regulates the Wnt/β-catenin signaling pathway to promote colorectal cancer progression via ac4C acetylation of KIF23 mRNA. | Jin, C., et al. 2022. J Exp Clin Cancer Res. 41: 345. PMID: 36522719
- Lysine 2-hydroxyisobutyrylation of NAT10 promotes cancer metastasis in an ac4C-dependent manner. | Liao, L., et al. 2023. Cell Res. 33: 355-371. PMID: 36882514
- NAT10 Drives Cisplatin Chemoresistance by Enhancing ac4C-Associated DNA Repair in Bladder Cancer. | Xie, R., et al. 2023. Cancer Res. 83: 1666-1683. PMID: 36939377
- NAT10 regulates the LPS-induced inflammatory response via the NOX2-ROS-NF-κB pathway in macrophages. | Zhang, Z., et al. 2023. Biochim Biophys Acta Mol Cell Res. 1870: 119521. PMID: 37307924
- NAT10-mediated ac4C tRNA modification promotes EGFR mRNA translation and gefitinib resistance in cancer. | Wei, W., et al. 2023. Cell Rep. 42: 112810. PMID: 37463108
- NAT10-mediated N4-acetylcytidine mRNA modification regulates self-renewal in human embryonic stem cells. | Liu, R., et al. 2023. Nucleic Acids Res. 51: 8514-8531. PMID: 37497776
- NAT10/ac4C/FOXP1 Promotes Malignant Progression and Facilitates Immunosuppression by Reprogramming Glycolytic Metabolism in Cervical Cancer. | Chen, X., et al. 2023. Adv Sci (Weinh). 10: e2302705. PMID: 37818745
- NAT10 Is Involved in Cardiac Remodeling Through ac4C-Mediated Transcriptomic Regulation. | Shi, J., et al. 2023. Circ Res. 133: 989-1002. PMID: 37955115
- NAT10 Phase Separation Regulates YTHDF1 Splicing to Promote Gastric Cancer Progression. | Liu, S., et al. 2024. Cancer Res. 84: 3207-3222. PMID: 39024555
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
NAT-10 Antibody (C-10) | sc-271141 | 200 µg/ml | $322.00 | |||
NAT-10 Antibody (C-10): m-IgG1 BP-HRP Bundle | sc-542678 | 200 µg Ab; 20 µg BP | $361.00 | |||
NAT-10 (C-10) Neutralizing Peptide | sc-271141 P | 100 µg/0.5 ml | $69.00 |